# A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity

> **NCT07721597** · EARLY_PHASE1 · RECRUITING · sponsor: **Zealand Pharma** · enrollment: 88 (estimated)

## Conditions studied

- Healthy Participants Study
- Overweight and Obese Adults
- First in Man Study to Evaluate Initial Safety

## Interventions

- **DRUG:** ZP6590, solution for injection
- **DRUG:** Placebo, solution for injection

## Key facts

- **NCT ID:** NCT07721597
- **Lead sponsor:** Zealand Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-09
- **Primary completion:** 2027-09-06
- **Final completion:** 2027-09-06
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2026-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07721597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07721597, "A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07721597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*